New Data: unlocking the potential of TCRm antibodies

Download the poster and explore the discovery of highly specific anti-WT1/HLA-A2 TCR-like antibodies

Keyway™ TCRm antibody discovery platform is revolutionizing immunotherapy development

In a significant study, Alloy Therapeutics researchers identified T Cell Receptor mimic (TCRm) antibodies with exceptional specificity for the Wilms Tumor 1 (WT1) antigen, ranked by National Cancer Institute as number one of the top targets for cancer immunotherapy. Identifying binders to WT-1/HLA-A2 is particularly challenging due to high homology with other peptides (M13L and PIGQ).

The Keyway TCRm Antibody Discovery Platform, powered by ATX-Gx™ transgenic mice, enabled the generation of highly specific antibodies with superior affinity and specificity compared to the three commercially available benchmark antibodies. This breakthrough has the potential to transform cancer treatment by enabling the development of TCRm-based therapies with enhanced efficacy and reduced off-target effects

Complete this form to download and view the poster

Name(Required)

Email(Required)

Organization(Required)

By clicking submit you consent to receive email communications about Alloy Therapeutics products and services and agree to our Terms. Your data will be processed in accordance with our Privacy Policy. You may opt out at any time.

Key Advantages of Alloy's TCRm Technology

Unmatched Specificity

Our TCRm antibodies demonstrate superior target specificity, minimizing off-target effects and improving safety profiles

Enhanced Affinity and Potency

Our TCRm antibodies demonstrate superior target specificity, minimizing off-target effects and improving safety profiles

Broad Applicability

This technology can be applied to various targets and diseases, expanding the potential of TCRm-based therapies beyond hematological cancers

Diverse Therapeutic Modalities

TCRm antibodies are adaptable to diverse formats, including bispecific antibodies and engineered cell therapies